Skip to content
Screener

Stoke Therapeutics, Inc. STOK Q1 2025 earnings

Reported May 13, 2025 · Before market open

Revenue$158.6MBeat by $127.1M
EPS$1.90Beat by $2.27
Revenue estimate$31.5M
EPS estimate-$0.37

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$8.2M
EPS estimate-$0.88

Financials

Q1 2025

Income statement

See full
Revenue$158.6M+3,661%
Operating income$111.2M+492%
Net income$112.9M+528%
EPS (diluted)$1.90+433%

Balance sheet

See full
Cash & equivalents$274.8M+53.9%
Total debt$6.0M-6.1%
Total equity$350.1M+149%
Total assets$406.9M+98.3%

Cash flow

See full
Operating cash flow$131.8M+637%
CapEx$152.0K+1,167%
Free cash flow$131.7M+636%

Valuation & ratios

Valuation

as of 03/31/25
See full
Market cap$359.62M-42.4%
Enterprise value$90.75M-79.9%
P/E7.2×—
P/S1.9×-77.7×

Profitability

See full
Operating margin20%+10.1pp
Net margin26.3%+13.3pp
FCF margin36.2%+18.4pp

Returns & leverage

See full
Return on equity20.5%+11.7pp
Debt / equity0×0.0×
Current ratio8.4×+3.0×

FAQ

When did Stoke Therapeutics, Inc. report Q1 2025 earnings?
Stoke Therapeutics, Inc. (STOK) reported Q1 2025 earnings on May 13, 2025 before market open.
What were Stoke Therapeutics, Inc.'s Q1 2025 revenue and EPS?
Stoke Therapeutics, Inc. reported revenue of $158.6M and eps of $1.90 for Q1 2025.
Did Stoke Therapeutics, Inc. beat estimates in Q1 2025?
Revenue beat the consensus estimate of $31.5M by $127.1M. EPS beat the consensus estimate of $-0.37 by $2.27.
How did Stoke Therapeutics, Inc.'s Q1 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 3661.1% from $4.2M a year earlier.
Where can I find Stoke Therapeutics, Inc.'s Q1 2025 SEC filings?
You can read the 8-K earnings release (0000950170-25-069783) and the 10-Q periodic report (0000950170-25-070296) directly on SEC EDGAR. The filing index links above go to sec.gov.